Hims & Hers Health (NYSE:HIMS) Stock Price Down 1.7% on Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report)’s share price traded down 1.7% on Thursday following insider selling activity. The company traded as low as $21.08 and last traded at $21.37. 2,170,933 shares were traded during mid-day trading, a decline of 68% from the average session volume of 6,775,989 shares. The stock had previously closed at $21.75.

Specifically, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $19.88, for a total value of $3,755,093.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $19.88, for a total value of $3,755,093.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 63,621 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $15.17, for a total transaction of $965,130.57. Following the completion of the sale, the insider now directly owns 154,345 shares of the company’s stock, valued at $2,341,413.65. The disclosure for this sale can be found here. Insiders sold a total of 915,990 shares of company stock worth $15,041,190 over the last 90 days. Corporate insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the topic of several research analyst reports. Piper Sandler lifted their price target on Hims & Hers Health from $11.00 to $13.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 7th. Guggenheim upped their price target on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Jefferies Financial Group reissued a “hold” rating and set a $15.00 price objective (down from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Finally, Canaccord Genuity Group raised their price target on Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.14.

View Our Latest Stock Report on HIMS

Hims & Hers Health Trading Down 0.8 %

The stock’s 50 day moving average price is $14.87 and its two-hundred day moving average price is $11.92. The firm has a market capitalization of $4.63 billion, a price-to-earnings ratio of -2,157.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMSGet Free Report) last posted its earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. During the same period in the previous year, the business earned ($0.05) earnings per share. Hims & Hers Health’s quarterly revenue was up 45.8% compared to the same quarter last year. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Belpointe Asset Management LLC raised its holdings in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after acquiring an additional 1,205 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Hims & Hers Health by 5.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after acquiring an additional 1,561 shares during the last quarter. Pathstone Family Office LLC raised its holdings in Hims & Hers Health by 2.8% in the 3rd quarter. Pathstone Family Office LLC now owns 65,876 shares of the company’s stock valued at $414,000 after acquiring an additional 1,824 shares during the last quarter. Swiss National Bank raised its holdings in Hims & Hers Health by 0.7% in the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after acquiring an additional 2,000 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in shares of Hims & Hers Health by 10.0% during the 1st quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock worth $344,000 after purchasing an additional 2,023 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Featured Articles

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.